Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Johnson and Johnson
Medtronic
Colorcon
Boehringer Ingelheim

Last Updated: June 28, 2022

TRICOR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Tricor, and when can generic versions of Tricor launch?

Tricor is a drug marketed by Abbvie and Abbvie Inc and is included in three NDAs. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and sixty-four patent family members in twenty-seven countries.

The generic ingredient in TRICOR is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.

Drug patent expirations by year for TRICOR
Drug Prices for TRICOR

See drug prices for TRICOR

Drug Sales Revenue Trends for TRICOR

See drug sales revenues for TRICOR

Recent Clinical Trials for TRICOR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of General Medical Sciences (NIGMS)Phase 2/Phase 3
The University of Texas Medical Branch, GalvestonPhase 2/Phase 3
Shriners Hospitals for ChildrenPhase 2/Phase 3

See all TRICOR clinical trials

Pharmacology for TRICOR
Anatomical Therapeutic Chemical (ATC) Classes for TRICOR
Paragraph IV (Patent) Challenges for TRICOR
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
TRICOR Tablets fenofibrate 48 mg 021656 1 2008-07-01
TRICOR Tablets fenofibrate 145 mg 021656 1 2007-10-19

US Patents and Regulatory Information for TRICOR

TRICOR is protected by two US patents.

Patents protecting TRICOR

Nanoparticulate fibrate formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods of treatment using nanoparticulate fenofibrate compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Abbvie TRICOR (MICRONIZED) fenofibrate CAPSULE;ORAL 019304-002 Feb 9, 1998 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-002 Nov 5, 2004 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Abbvie TRICOR (MICRONIZED) fenofibrate CAPSULE;ORAL 019304-003 Jun 30, 1999 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TRICOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-002 Nov 5, 2004 See Plans and Pricing See Plans and Pricing
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-002 Nov 5, 2004 See Plans and Pricing See Plans and Pricing
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004 See Plans and Pricing See Plans and Pricing
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for TRICOR

See the table below for patents covering TRICOR around the world.

Country Patent Number Title Estimated Expiration
Japan H08501073 See Plans and Pricing
European Patent Office 2266542 Libération regulée de compositions nanoparticulaires (Controlled release nanoparticulate compositions) See Plans and Pricing
European Patent Office 2283864 Composition liquide contenant des nanoparticules stabilisées d'une substance active (Liquid dosage compositions fo stable nanoparticulate active agents) See Plans and Pricing
Cyprus 1111344 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Colorcon
Dow
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.